/TELO
TELO Stock - Telomir Pharmaceuticals, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$1.41+2.92%
+$0.04 (+2.92%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.17
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.55
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TELO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.40 – $1.42
TARGET (TP)$1.62
STOP LOSS$1.30
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.46
52W High$5.40
52W Low$1.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-12,242,174 | $-3,942,048 | $-854,147 | $-138,131 |
| Net Income | $-16,532,716 | $-13,071,864 | $-854,147 | $-138,131 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-0.56 | $-0.44 | $-0.03 | $-0.00 |
Company Overview
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$15
Average Target
↑ 963.8% Upside
Now
$15
Low
$15
Average
$15
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 21st 2025 | Rodman & Renshaw | Initiation | Buy | $15 |
Earnings History & Surprises
TELOBeat Rate
40%
Last 5 quarters
Avg Surprise
-85.1%
EPS vs Estimate
Beats / Misses
2/3
Last 12 quarters
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
-300.0%
$-0.20vs$-0.05
Q1 25
-100.0%
$-0.10vs$-0.05
Q2 25
+30.0%
$-0.07vs$-0.10
Q3 25
-112.5%
$-0.17vs$-0.08
Q4 25
+57.1%
$-0.03vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.08 | $-0.17 | -112.5% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $-0.05 | $-0.10 | -100.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.05 | $-0.20 | -300.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | — | $-0.05 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.23 | — | — |
Q1 2024 | Mar 29, 2024 | — | $-0.32 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.06 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.05 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.02 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.02 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.00 | — | — |
Latest News
Telomir Pharma Announces Results From Comprehensive Series Of IND-Enabling GLP Toxicology And Safety Pharmacology Studies For Telomir-1
📈 PositiveBenzinga•Dec 18, 2025, 12:32 PM
Telomir Pharmaceuticals Announces Results From Good Laboratory Practice Studies For Telomir-1; Says Telomir-1 Was Generally Well Tolerated, With No Treatment-related Adverse Or Dose-limiting Toxicities Observed. Observed Findings Were Limited, Reversible, And Considered Non-adverse
📈 PositiveBenzinga•Dec 17, 2025, 09:16 PM
Telomir Pharma Reports New Preclinical Findings Demonstrating Its Lead Therapeutic Candidate, Telomir-1, Reduced PSA Levels In Androgen-Responsive Human Prostate Cancer Cells
📈 PositiveBenzinga•Nov 25, 2025, 01:06 PM
Telomir Pharmaceuticals Reports Telomir-1 Kills Aggressive Human Leukemia Cells In Preclinical In Vitro Study Expanding Oncology Profile To Blood Cancers
📈 PositiveBenzinga•Nov 21, 2025, 12:31 PM
Telomir Pharmaceuticals Announces Telomir-1 Shown To Kill Aggressive Human Leukemia Cells
📈 PositiveBenzinga•Nov 20, 2025, 09:05 PM
Telomir Pharmaceuticals Announces Preclinical Findings Showing Telomir-1 Markedly Lowered Intracellular Iron Levels At Submicromolar Concentrations In Human Keratinocytes
📈 PositiveBenzinga•Nov 12, 2025, 01:04 PM•Also:
Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 11:00 PM
Telomir Pharmaceuticals shares are trading higher after the company reported preclinical data from a mouse study evaluating Telomir-1's impact on CASP8 and GSTP1 genes.
📈 PositiveBenzinga•Oct 23, 2025, 11:34 AM
Telomir Pharmaceuticals Reports Preclinical Data From Mouse Study Evaluating Impact Of Telomir-1's Impact Of CASP8 And GSTP1 Genes
➖ NeutralBenzinga•Oct 23, 2025, 11:33 AM
Telomir Pharmaceuticals Reports Preclinical Data From Aggressive Prostate-Cancer Model Evaluating Its Investigational Compound Telomir-1.
➖ NeutralBenzinga•Oct 22, 2025, 08:25 PM
Telomir Pharmaceuticals To Acquire TELI Pharma, Unifying Global Rights To Telomir-1 Cancer And Aging Therapy
📈 PositiveBenzinga•Oct 21, 2025, 11:36 AM
Telomir Pharmaceuticals Signs Binding LOI To Acquire TELI Via Stock-For-Stock Exchange, Securing Global Rights To Telomir-1
📈 PositiveBenzinga•Oct 20, 2025, 10:15 PM
Telomir-1 Demonstrates Anti-Tumor Activity In Pancreatic Cancer Models, Reinforcing Epigenetic And Metabolic Impact Across Multiple Cancers
📈 PositiveBenzinga•Oct 14, 2025, 12:10 PM
Telomir Pharmaceuticals shares are trading higher after the company announced new findings for Telomir-1.
📈 PositiveBenzinga•Oct 9, 2025, 01:05 PM
Telomir Pharmaceuticals Announces Findings in Targeting Triple-Negative Breast Cancer with Telomir-1
📈 PositiveBenzinga•Oct 9, 2025, 11:34 AM
Market-Moving News for October 9th
➖ NeutralBenzinga•Oct 9, 2025, 11:16 AM•Also: ,
Telomir Pharmaceuticals shares are trading higher after the company announced new findings for Telomir-1.
📈 PositiveBenzinga•Oct 8, 2025, 08:33 PM
Telomir Pharmaceuticals Says Telomir-1 Shuts Down Cellular Energy Pathways, Mitochondrial Function In Aggressive Breast Cancer Cells; Plans To Expand Studies To Pancreatic, Leukemia Models, Conduct Further Animal Studies For IND Submission
📈 PositiveBenzinga•Oct 8, 2025, 08:11 PM
Telomir Pharmaceuticals Reports Telomir-1 Selectively Kills Triple-Negative Breast Cancer Cells By Disrupting Iron-Dependent Energy Pathways
📈 PositiveBenzinga•Oct 8, 2025, 08:09 PM
Telomir Pharmaceuticals shares are trading higher after the company reported preclinical data showing Telomir-1 reactivates key tumor suppressor genes via DNA methylation reset in prostate cancer models.
📈 PositiveBenzinga•Oct 7, 2025, 04:04 PM
Frequently Asked Questions about TELO
What is TELO's current stock price?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is currently trading at $1.41 per share. The stock has moved +2.92% today.
What is the analyst price target for TELO?
No analyst price targets are currently available for this stock.
What sector is Telomir Pharmaceuticals, Inc. Common Stock in?
Telomir Pharmaceuticals, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TELO's market cap?
Telomir Pharmaceuticals, Inc. Common Stock has a market capitalization of $0.05 billion, making it a small-cap company.
Does TELO pay dividends?
No, Telomir Pharmaceuticals, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
COEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
GNTA
Genenta Science S.p.A.
$1.45
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
Explore stocks similar to TELO for comparison